He’s part of a healthcare team that has sourced equity for biotech firms like: Bluebird Bio ($400 million follow-on) — a cancer immunotherapy company that rivals Kite Pharma — and gene therapy firms Audentes (a $75 million IPO) and Regenx (a $139 …
( read original story …)